Ghana Receives Africa's First NovaSeq X Plus Sequencer to Address Cancer Care Disparities
Key Insights
Yemaachi Biotech (search) and Illumina have introduced Ghana's first NovaSeq X Plus (search) sequencer, the most powerful genomic sequencer manufactured by Illumina, to accelerate cancer (search) research in African populations.
The initiative supports The African Cancer (search) Atlas (TACA), which aims to create the world's most comprehensive cancer genomic database focused on African populations to address historical underrepresentation in global cancer research.
The NovaSeq X Plus (search) can generate more than double the number of genomes compared to previous sequencers, providing unprecedented speed, scale and accuracy for genetic sequencing.
Yemaachi Biotech (search), a pioneering genomics research company based in Ghana, and Illumina (NASDAQ: ILMN), a global leader in sequencing technology, have announced the arrival of the NovaSeq X Plus (search) sequencer to Ghana. This marks the first installation of its kind in the country and represents a significant milestone in addressing cancer (search) care inequities across African populations.
The NovaSeq X Plus (search), described as the most powerful sequencer manufactured by Illumina to date, is designed to accelerate research that promises to reduce disparities in cancer (search) care for individuals of African ancestry. This development comes at a critical time when cancer diagnosis and treatment globally are rapidly evolving from traditional one-size-fits-all approaches to precision medicine tailored to individual genetic profiles.
Addressing Historical Research Gaps
Cancer (search) research examining the underlying genetic makeup of cancer has historically been undertaken predominantly among individuals of European ancestry. This focus has meant that diagnosis and treatment pathways have not been optimized for individuals of African ancestry, continuing to contribute to inequities in cancer outcomes globally.
"As pharma seeks to make treatments more and more precise, the need for more inclusive genomic data to inform drug discovery has never been greater," said Akwasi Asabere, VP Partnerships at Yemaachi. "The African population is the most genetically diverse population in the world and has the potential to transform how we create new drugs."
The African Cancer Atlas Initiative
Earlier this year, Yemaachi announced the launch of The African Cancer (search) Atlas (TACA), an initiative that seeks to address the significant underrepresentation of African genomic data in global cancer research. The project aims to create the world's most comprehensive cancer genomic database focused on African populations.
"Our aim is to create the world's most diverse cancer (search) bio-database to inform the development of the next generation of cancer drugs that are effective across diverse populations across the world," Asabere explained.
Enhanced Sequencing Capabilities
The NovaSeq X Plus (search) will provide the sequencing throughput and capacity necessary to make the TACA database a reality. According to Bridget Mogale, Illumina Country Manager-Africa, "The NovaSeq X Plus can generate more than double the number of genomes of our prior sequencers. It has unprecedented speed, scale and accuracy and pushes the limits on what is possible with genetic sequencing."
Yaw Bediako, CEO of Yemaachi, emphasized the significance of this technological advancement: "Illumina's NovaSeq X Plus (search) will help provide the sequencing throughput and capacity to make this database a reality. With NovaSeq X Plus, Yemaachi is well positioned to reach their goals more quickly to help transform the lives of cancer (search) patients."
Public Health Impact
According to the World Health Organization Global Cancer (search) Observatory's cancer incidence and mortality database, cancer remains a significant public health challenge across Africa, with the number of new cases rising rapidly each year. The precision medicine approach recognizes that each person's cancer is as unique as their fingerprint, fundamentally altering how cancer is detected and treated.
Mogale highlighted Illumina's commitment to global health equity: "At Illumina, we are driven by the power of genomics to positively impact the world and are deeply committed to improving global health. We are pleased to have Yemaachi bring in this powerful sequencer to better understand cancers in populations of African descent and address existing disparities in current data sets."
Future Implications
This partnership represents a significant step toward expanding diversity in genomics research and addressing gaps in current datasets. Established in 2020, Yemaachi Biotech (search) applies cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of effective cancer (search) detection and treatment strategies across all ethnicities.
With headquarters in Accra and offices in Washington, DC and Nairobi, Yemaachi is building sustainable research and community partnerships to reduce the cancer (search) burden across Africa. The installation of the NovaSeq X Plus (search) positions the company to significantly advance its mission of promoting equitable access to precision medicine across the continent.